Analysts expect that Check-Cap Ltd. (NASDAQ:CHEK) will post earnings per share of ($0.13) for the current quarter, Zacks reports. Zero analysts have provided estimates for Check-Cap’s earnings. Check-Cap posted earnings of ($0.15) per share during the same quarter last year, which would suggest a positive year over year growth rate of 13.3%. The firm is expected to issue its next earnings report on Monday, August 21st.

According to Zacks, analysts expect that Check-Cap will report full-year earnings of ($0.62) per share for the current fiscal year, with EPS estimates ranging from ($0.65) to ($0.58). For the next financial year, analysts forecast that the firm will report earnings of ($0.69) per share, with EPS estimates ranging from ($0.86) to ($0.51). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Check-Cap.

CHEK has been the subject of a number of research reports. Zacks Investment Research raised shares of Check-Cap from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a report on Wednesday, May 24th. ValuEngine raised shares of Check-Cap from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Finally, Maxim Group reissued a “buy” rating on shares of Check-Cap in a report on Tuesday, May 30th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Check-Cap has an average rating of “Hold” and an average target price of $5.00.

An institutional investor recently raised its position in Check-Cap stock. Knott David M raised its position in Check-Cap Ltd. (NASDAQ:CHEK) by 1.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 162,871 shares of the medical research company’s stock after buying an additional 3,000 shares during the period. Knott David M owned about 1.05% of Check-Cap worth $349,000 at the end of the most recent quarter. 13.35% of the stock is owned by institutional investors.

Shares of Check-Cap (NASDAQ:CHEK) traded down 1.09% during trading on Friday, reaching $1.81. The company’s stock had a trading volume of 45,344 shares. Check-Cap has a 12 month low of $1.24 and a 12 month high of $3.42. The company’s 50-day moving average is $1.87 and its 200-day moving average is $2.08. The company’s market capitalization is $28.29 million.

TRADEMARK VIOLATION WARNING: This piece was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at

Check-Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Get a free copy of the Zacks research report on Check-Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with's FREE daily email newsletter.